share_log

邁博藥業(02181.HK)地舒單抗臨床試驗申請獲批

Application for clinical trial of desuximab from 02181.HK Pharmaceutical Co., Ltd. Approved

即市頭條 ·  Jan 13, 2022 15:40

Maibo Pharmaceutical-B (02181.HK) announced that China's State Drug Administration (SDA) has approved an application for a clinical trial of CMAB807X (deschumab) in the treatment of bone metastasis of tumors.

CMAB807X is a kind of human IgG2 monoclonal antibody, which is expected to be used to treat bone metastasis of tumor and giant cell tumor of bone and prevent bone related events in patients with solid tumor bone metastasis and multiple myeloma after the application of new drug is approved.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment